Evidence map›Paper›PMID 29926545›Full record

ArticleTuberculosis and respiratory diseases2019

The Effects of Retinoic Acid and MAPK Inhibitors on Phosphorylation of Smad2/3 Induced by Transforming Growth Factor β1.

Sang Hoon Lee, Ju Hye Shin, Mi Hwa Shin, Young Sam Kim, Kyung Soo Chung, Joo Han Song, Song Yee Kim, Eun Young Kim, Ji Ye Jung, Young Ae Kang and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Tuberculosis and respiratory diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Nanomedicine for Cancer and Autoimmune Immunotherapy.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sang Hoon LeeDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7706-5318
Ju Hye ShinDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Mi Hwa ShinDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Young Sam KimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Kyung Soo ChungDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Joo Han SongDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Song Yee KimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Eun Young KimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Ji Ye JungDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Young Ae KangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Joon ChangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
Moo Suk ParkDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine, Seoul, Korea. pms70@yuhs.ac.ORCID https://orcid.org/0000-0003-0820-7615
Yonsei University Health System · KRSeoul National University Bundang Hospital · KR

Funding

University College of Medicine 6-2008-0150
6 · The paper itself

Abstract

backgroundTransforming growth factor β (TGF-β), retinoic acid (RA), p38 mitogen-activated protein kinase (MAPK), and MEK signaling play critical roles in cell differentiation, proliferation, and apoptosis. We investigated the effect of RA and the role of these signaling molecules on the phosphorylation of Smad2/3 (p-Smad2/3) induced by TGF-β1.

methodsA549 epithelial cells and CCD-11Lu fibroblasts were incubated and stimulated with or without all-trans RA (ATRA) and TGF-β1 and with MAPK or MEK inhibitors. The levels of p-Smad2/3 were analyzed by western blotting. For animal models, we studied three experimental mouse groups: control, bleomycin, and bleomycin+ATRA group. Changes in histopathology, lung injury score, and levels of TGF-β1 and Smad3 were evaluated at 1 and 3 weeks.

resultsWhen A549 cells were pre-stimulated with TGF-β1 prior to RA treatment, RA completely inhibited the p-Smad2/3. However, when A549 cells were pre-treated with RA prior to TGF-β1 stimulation, RA did not completely suppress the p-Smad2/3. When A549 cells were pre-treated with MAPK inhibitor, TGF-β1 failed to phosphorylate Smad2/3. In fibroblasts, p38 MAPK inhibitor suppressed TGF-β1-induced p-Smad2. In a bleomycin-induced lung injury mouse model, RA decreased the expression of TGF-β1 and Smad3 at 1 and 3 weeks.

conclusionRA had inhibitory effects on the phosphorylation of Smad induced by TGF-β1

Indexed as

MEKsMitogen-Activated Protein KinasesRetinoic AcidSmad ProteinsTransforming Growth Factor Beta

Identifiers

PMID29926545
PMCPMC6304329
OpenAlexW2808766334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.